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Summary
Purpose: To unravel the mechanism of action of neurostimulation as a treatment for
seizures, functional neuroimaging tools allow minimally invasive research in humans.
We performed single-photon emission computed tomography (SPECT) in patients with
epilepsy, treated with vagus nerve stimulation (VNS). Changes in regional cerebral
blood flow (rCBF) at the time of initial stimulation as well as after chronic treatment
were correlated with long-term clinical efficacy.
Methods: In this pilot study, 27 patients (14 female and 13 male) who were treated
with VNS at Ghent University Hospital for refractory epilepsy underwent a 99mTc-ECD
(ethyl cystein dimer) SPECTactivation study at the time the first stimulation train was
administered. 12 patients underwent an additional 99mTc-ECD SPECTactivation study
6 months later. Image acquisition was performed on a high-resolution triple-headed
gamma camera. Significant rCBF changes were correlated with prospectively assessed
clinical efficacy data.
Results: Significant rCBF changes were found in the thalamus, the hippocampus and
the parahippocampal gyrus. Acute limbic hyper-perfusion and chronic thalamic hypo-
perfusion correlate with positive clinical efficacy.
Conclusions: Acute and chronic electrical stimulation of the vagus nerve induces rCBF
changes that can be measured by SPECTon a group-basis. The thalamus and the limbic
system are thought to play a key role in the mechanism of action of VNS.
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In view of the extensive number of patients who
cannot benefit from currently available treatments
for epilepsy, the evaluation of the therapeutic
potential of peripheral and intracerebral neurosti-
mulation has regained interest in the past 15 years.
Identification of the nervous tissue structures to be
targeted and the optimal stimulation parameters to
achieve efficacy and maintain safety are the main
issues to be clarified. Progress in ongoing research
unravelling the complex pathophysiology of the
epileptogenic network and the mechanism by which
electrical stimulation may interfere, suggest pro-
mising practical applicability of different neurosti-
mulation modalities for patients with refractory
epilepsy.
Vagus nerve stimulation (VNS) is currently a rou-
tinely applied neurostimulationmodality for patients
with medically or surgically refractory epilepsy with
over 50,000 patients treated worldwide.1 Several
open and controlled studies have established the
efficacy and safety of VNS both during short and
long-term follow-up.2—5 For patients with refractory
epilepsy VNS is a cost-beneficial treatment.6
The exact mechanism by which VNS exert its anti-
epileptic effect is not fully understood.7 Elucidation
of this mechanism might be an important step for-
ward in the identification of predictive factors for
positive outcome or guidelines for optimized stimu-
lation regimens. The vagus nerve communicates
with the nucleus of the solitary tract in the brain
stem. From this location, it may influence various
parts of the brain as it has widespread cortical and
subcortical anatomical and functional connec-
tions.8,9 Functional imaging techniques using acti-
vation paradigms to evaluate regional cerebral
blood flow (rCBF) changes are suitable for studying
VNS-induced effects in humans in a minimally inva-
sive way. Several human functional neuroimaging
studies have shown the possibility of measuring rCBF
changes induced by VNS and in this way identified
potentially important central nervous system struc-
tures. As most studies were performed in small
and heterogeneous patient populations a consensus
on key structures or type of rCBF changes that
are involved has not been reached. The majority
of studies reporting an increase in rCBF used posi-
tron emission tomography (PET)10,11 or more
recently also functional magnetic resonance ima-
ging (fMRI)12—15 whereas those reporting a decrease
used SPECT.16—18
The current pilot study aimed at describing
alterations in rCBF triggered by VNS in a larger
and fully documented patient group (N = 27).
Long-term clinical follow-up was available for allincluded patients. Once we identified brain regions
with significantly altered rCBF, we correlated these
findings with clinical efficacy data obtained after a
considerable follow-up period at a timewhen poten-
tial clinical efficacy of VNS was clear. We also
explored if baseline SPECT data compared to a
gender- and age-matched control group could pro-
vide predictive factors for VNS efficacy. Based on
previous research and the currently available infor-
mation in the literature within this context, we
hypothesized involvement of the thalamus, cere-
bellum, parahippocampal gyrus, amygdala and
hippocampus for all conducted analyses.Patients and methods
Patient population
Twenty-seven patients (14 females, 13 males) with
refractory epilepsy were included in our study. On
the basis of an extensive presurgical evaluation by a
multidisciplinary epilepsy team, all patients were
considered unsuitable candidates for resective sur-
gery because of non-localizing findings or localiza-
tion of the epileptic focus in functional brain tissue.
The presurgical evaluation protocol has been
described previously.19 All patients were treated
with chronic anti-epileptic drug (AED) polytherapy.
AED dosages were not changed during the first 12
months of follow-up. The individual patients char-
acteristics are summarized in Table 1.
All patients gave informed consent based on the
SPECT study protocol approved by the local ethics
committee. The surgical implantation procedure of
the Neurocybernetic Prosthesis System (model 100
or 101; Cyberonics, Webster, TX, USA) and the ramp-
ing-up procedure of the stimulator have been
described previously.3
Patients were followed up at the epilepsy clinic at
regular intervals and relevant clinical data on sei-
zure frequency, seizure severity and side effects
were prospectively collected using a seizure diary
kept by the patient or caregiver.
Activation paradigm (Fig. 1)
All patients underwent a split-dose (2  555 MBq)
99mTc-ECD SPECT at the time of initial VNS. The
technical specifications of the split-dose activation
study set-up have been described earlier.20 The first
dose was injected in baseline conditions (acute
baseline condition). The second dose was injected
immediately following an initial 30-s stimulation
train (30 Hz, 500 ms, 0.25 mA) (acute activation
condition). The first 12 patients included in the study
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Table 1 Patient characteristics and clinical efficacy of vagus nerve stimulation (the first 12 patients underwent
SPECT after 6 months of follow-up)
Patient Gender Age
(years)
Seizure
duration
(years)
Follow-up
(months)
Seizure
type
CPS  SG/
month
before VNS
% Reduction in
seizure frequency
at maximum
follow-up
AEDs
before
VNS
AEDs at
maximum
follow-up
1 F 31 9 71 CPS  SG 16 81 3 3
2 F 16 11 64 CPS  SG/SPS 200 100 4 3
3 F 38 30 67 CPS  SG 8 0 3 3
4 F 12 5 54 CPS  SG 12 50 4 5
5 M 28 16 52 CPS 30 70 2 3
6 F 39 16 53 CPS  SG 3 70 4 4
7 F 44 23 50 CPS  SG 10 40 3 2
8 M 36 30 50 CPS  SG 4 50 4 3
9 M 49 35 49 CPS 30 80 4 6
10 F 41 19 46 CPS 15 80 3 3
11 M 35 13 46 CPS + SG 4 0 3 4
12 F 26 25 45 CPS  SG 120 66 3 3
13 F 22 16 35 CPS 10 60 3 3
14 F 26 24 38 CPS  SG 90 90 3 3
15 M 37 23 38 CPS 30 40 3 4
16 M 47 43 30 CPS + SG 30 90 4 4
17 M 10 8 30 CPS 50 60 3 3
18 M 40 3 29 CPS  SG 8 50 4 3
19 F 44 34 28 CPS/SPS  SG 5 70 3 3
20 F 41 39 29 CPS 4 50 2 3
21 F 30 16 29 CPS  SG 8 50 4 4
22 M 27 9 29 CPS 7 50 3 4
23 M 31 11 27 CPS 4 25 4 4
24 M 36 20 30 CPS 30 0 3 4
25 M 21 8 19 CPS  SG 10 95 3 3
26 M 25 20 19 CPS  SG 10 50 2 2
27 F 36 34 19 CPS  SG 7 60 3 3
CPS: complex partial seizure, SG: secondary generalisation, VNS: vagus nerve stimulation, AED: anti-epileptic drug, M: male, F:
female, SPS: simple partial seizure.
Figure 1 Acute and chronic SPECTactivation paradigm.
I: vagus nerve stimulation output intensity, mA = milliam-
peres, t = time, : 99mTc injection, 1: acute baseline con-
dition, 2: acute stimulation condition, 3: chronic baseline
condition, 4: chronic activation condition.agreed toundergo this split-doseactivationparadigm
againafter6monthsof stimulation.Thefirstdosewas
injected with VNS parameters that had been pro-
grammed over a follow-up period of 6 months to
reach optimal clinical efficacy with minimal side
effects (chronic baseline condition). VNS parameters
had been kept stable in the weeks preceding the
SPECT study. The second dose was injected after an
additional 30-s stimulation train (30 Hz, 500 ms,
0.25 mA) (chronic activation condition).
For the analysis the acute baseline and acute
activation condition were compared; the chronic
baseline and chronic activation condition were com-
pared; and the acute and chronic baseline were
compared.
99mTc-ethyl cysteine dimer (ECD) (Neurolite;
DuPont Pharmaceuticals Ltd., Brussels, Belgium)
was used to estimate rCBF. During the scanning
procedure a neurologist was present on-site to clini-
cally evaluate patients and detect possible clinical
seizures.Age- and sex-matched healthy volunteers
The baseline, pre-stimulus SPECT scans of the
patients were compared with those of age- and
sex-matched healthy individuals. Carefully screened
702 K. Vonck et al.healthy volunteers underwent the same scanning
procedure with 925 MBq 99mTc-ECD under standard
circumstances. For this study, 30 healthy volunteers
(16 females, 14 males; mean age 32.2  8.2 years)
from the GOAHEAD project were included after age
and sex matching to the epilepsy patients.21 To
investigate a possible predictive value of the acute
baseline condition for clinical outcome, all 99mTc-ECD
perfusion scans were compared with those of the
healthy volunteers and regional z-scores were
derived. The z-scores were defined as the patient’s
99mTc-ECD uptake expressed in standard deviations
from the normal template (Brass; Nuclear Diagnos-
tics).
Image acquisition and processing
All patient and healthy volunteer SPECT images
were acquired using a GCA-9300 triple-head system
(Toshiba, Tokyo, Japan) with high-resolution fan-
beam collimation, uniform So¨renson attenuation
correction (effective attenuation coefficient,
0.09 cm1), and triple-energy window scatter cor-
rection.22 Reconstructed images were transferred in
Interfile format onto a central image processing
system (HERMES; Nuclear Diagnostics, Ltd., Stock-
holm, Sweden). Intra-individual scans were auto-
matically co-registered by means of 6 rigid
parameters (shift and rotate) using a count differ-
enceminimization algorithm (MultiModality; Nuclear
Diagnostics, Ltd.). Theaverage imageof eachpatient
was then anatomically standardized onto an in-house
constructed database template positioned in the
coordinates of Talairach andTournoux23 using a linear
nine-parameter (shift, scale, rotation) transforma-
tion.22 Activity changes were calculated automati-
cally in 39 predefined volumes of interest (VOIs)
including the whole-brain grey matter. In addition,
the mesial temporal cortex VOI of a previously used
whole-brain VOI region map was subdivided into
the amygdala, hippocampus, and parahippocampal
gyrus. For each individual subject and scan, the VOI
activity counts were calculated per voxel and nor-
malized onto the total number of counts in the
complete VOI set of the scan.
Statistics
After validation of normal distribution of the indi-
vidual values (Kolmogorov—Smirnov test) we
performed a one-sample t-test to investigate dif-
ferences in pre- and post-stimulation differences in
uptake between different brain regions. All correla-
tions were investigated using Pearson’s coefficient.
Statistics were calculated with SPSS (v10.0 for Win-
dows, SPSS Inc., Heverlee, Belgium).Results
The mean patient age at the time of implantation
was 32 years (range: 10—49, S.D. = 10.2); the mean
duration of epilepsy was 20 years (range: 3—43
years, S.D. = 10.9).
Clinical efficacy
Themean number of AEDwas 3 (range: 1—4) and this
number remained unchanged at maximal follow-up.
The average follow-up period for the whole
patient group was 42 months (range: 19—71 months;
S.D. = 14.7). The number of reported seizures pre-
VNS ranged from 3 to 200 with a mean of 28 seizures
per month. At maximum follow-up period there was
a mean reduction of seizure frequency of 57%
(range: 0—100%; S.D. = 27.3). For the total group,
14 patients became responders and showed a >50%
reduction in seizure frequency. In nine patients, VNS
resulted in a moderate seizure reduction (30—50%),
while four patients showed only minor or no effect
of VNS (reduction <30%).
Acute baseline condition versus acute
stimulation condition (Table 2)
A significant decrease in rCBF was found in the right
and left parahippocampal gyrus (p < 0.001; p =
0.026), the left thalamus (p = 0.035) and the right
hippocampus (p = 0.016). These rCBF changes
reached a higher lever of significance when non-
responders (<30% seizure frequency reduction,
n = 4) were excluded from the analysis: right and left
parahippocampal gyrus (p < 0.001; p = 0.017), left
thalamus (p = 0.019), right hippocampus (p = 0.010).
Acute baseline condition versus chronic
baseline condition
A decrease in 99mTc-ECD uptake between the acute
baseline condition and the chronic condition was
found in the left thalamus (p = 0.034). No other
brain regions of hypo- or hyper-perfusion could be
discovered. Results are summarized in Table 2.
When excluding non-responders (<30% seizure fre-
quency reduction, n = 4) in this analysis the
decreased left thalamic blood flow gained signifi-
cance ( p = 0.009) and also the right thalamus now
showed a significant decrease in rCBF ( p = 0.028).
Chronic baseline condition versus chronic
activation condition
An additional 30-s stimulus of 0.25 mA after chronic
stimulation during 6 months yielded an increased
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Table 2 Ratios of different study conditions and significance in hypothesized regions
Brain region Acute stimulation condition/
acute baseline condition
(n = 27)
Chronic baseline condition/
acute baseline condition
(n = 12)
Chronic activation condition/
chronic baseline condition
(n = 12)
Mean t p
(2-tailed)
Mean t p
(2-tailed)
Mean t p
(2-tailed)
Left cerebellum 1.008 1.189 NS 1.015 0.746 NS 0.978 1.428 NS
Left thalamus 0.977 2.230 0.035 0.950 2.417 0.034 1.035 3.180 0.011
Left amygdala 0.994 0.230 NS 1.036 0.954 NS 1.010 0.461 NS
Left gyrus
parahippocampus
0.974 2.369 0.026 1.023 0.887 NS 0.993 0.462 NS
Left hippocampus 1.000 0.005 NS 1.005 0.178 NS 1.017 0.794 NS
Right cerebellum 1.012 1.189 NS 1.012 0.874 NS 0.963 1.980 NS
Right thalamus 1.000 0.033 NS 0.969 1.656 NS 1.0127 1.192 NS
Right amygdala 1.016 0.789 NS 1.012 0.257 NS 1.020 0.786 NS
Right gyrus
parahippocampus
0.972 4.012 <0.001 0.989 0.454 NS 0.994 0.575 NS
Right hippocampus 0.971 2.567 0.016 0.980 0.609 NS 0.870 1.321 NS
Figure 2 Positive correlation between increased left
temporal medial rCBF and increasing clinical efficacy
(acute stimulation condition correlated with outcome).rCBF in the left thalamus ( p = 0.011). No other
regions among the hypothesized regions of invol-
vement of altered rCBF could be established. In
addition no changes in rCBF could be found for the
other brain regions, after Bonferroni correction for
multiple comparisons. Results are also given in
Table 2.
Baseline SPECT versus healthy volunteers
When considering the regional z-scores of the whole
group of patients, there were a number of pre-
stimulus differences for the patients versus
age- and gender-matched normals. Comparing
the previously hypothesized brain regions in the
whole patient group, relatively hyperperfused areas
were present in the left parahippocampal gyrus
( p = 0.036), left amygdala ( p = 0.009), and left
hippocampus ( p = 0.035). Among the regions not
previously implied in the mechanism of action of
VNS, after Bonferroni correction, a relative hypo-
perfusion was present in the right caudate head
( pcorr = 0.0016).
Correlations between rCBF changes and
long-term clinical efficacy
When correlating the rCBF changes in the acute
stimulation condition with the absolute percentage
of seizure reduction, a significant correlation was
found with the left medial temporal inferior region
(r = 0,459, puncorr = 0.016). Fig. 2 demonstrates
that an increased left temporal medial inferior
blood flow is positively correlated with an increasing
efficacy.
The chronic activation condition did not produce
rCBF alterations correlating with clinical efficacy.Correlation of rCBF changes between the chronic
baseline condition and the clinical efficacy gener-
ated a positive correlation between a decreasing
left thalamic rCBF and an increasing clinical efficacy
(r = 0.615, puncorr = 0.033) (Fig. 3). No other corre-
lations could be established.
Correlation of the pre-stimulus z-scores with the
clinical outcome percentage produced no significant
result.Discussion
Despite the growing number of patients treated with
VNS and the successful exploration of novel and
promising indications within and even outside the
neurological field, the precise mechanism of action
of VNS in influencing the brain in a therapeutically
efficacious manner, remains to be elucidated. Treat-
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Figure 3 Positive correlation of a decreasing left tha-
lamic rCBF and increasing clinical efficacy (chronic base-
line condition correlated with outcome).ment for epilepsy as well as other pathological
conditions is mainly based on evidence-based infor-
mation rather than on rational deductions from
basic research in the pathophysiology or the mode
of action of neurostimulation because many of these
issues currently remain unclarified. This is also the
case for many other medical treatments especially
for neurological conditions that arise from a com-
plex physiological substrate like the human nervous
system.
In the past 10 years interesting findings have
arisen from different types of research. However,
these findings have so far not been useful for prac-
tical application in the sense that predictive factors
for clinical response or practical guidelines for opti-
mising stimulation parameters have been identified.
Functional imaging techniques such as PET, SPECT
and more recently fMRI allow to non-invasively
measure neuronal activity as reflected by changing
rCBF.24 Based on the established clinical efficacy of
VNS as a treatment for epileptic seizures, a condi-
tion of cortical origin, it is supposed that electrical
stimulation of the vagus nerve can acutely and/or
chronically change neuronal activity within the
brain. Identification of the localization(s) and nat-
ure of these supposed changes may be investigated
with the mentioned techniques. As VNS in a clinical
setting consists of an implanted programmable bio-
medical system that can be turned off and on,
activation studies are suitable to evaluate intracer-
ebral functioning in relation to electrical stimula-
tion at a certain distance. Moreover, the correlation
of VNS-induced rCBF changes with VNS-induced
reduction in seizure frequency is a powerful experi-
mental design that can be performed in humans to
study the mechanism of action and potentially iden-
tify predictive factors for positive clinical outcome.In the past, different modalities of functional
imaging have been used in VNS research, some of
them in small patient groups at a time when VNS was
still an emerging novel treatment. There are limited
numbers of studies in animals.25 Interesting results
firstly arose from a study by Henry et al.11 who
examined the acute effects of VNS using PET. Cor-
relation of acute VNS-induced rCBF alterations and
chronic therapeutic responses showed that bilater-
ally increased thalamic rCBF correlated with a
decreased seizure frequency in responders after 3
months of treatment.26 Several other studies, using
PET, SPECTand recently fMRI examined rCBF altera-
tions after chronic VNS treatment leading to further
identification of potential key structures involved in
the mechanism of action. However no uniform func-
tional pathway addressed by VNS to exert its effect
from the cervical part of the vagus nerve to the
brain cortex was outlined.
In the current study 27 patients were included
with a mean follow-up period of 42 months. In
contrast to many other anti-epileptic treatments
such as anti-epileptic drugs, it is known from
long-term clinical studies with VNS that efficacy
increases over a time period of several months.
Meaningful correlations of functional imaging
results with clinical efficacy demand prospectively
assessed long-term clinical follow-up.
In the acute stimulation condition we found a
decreased rCBF in left thalamus, right hippocampus
and bilateral parahippocampal gyri. Because we
used a more detailed region map for the medial
temporal cortex, we were able to identify temporal
lobe substructures with altered rCBF. In previously
published studies from our group using the same
protocol in a smaller patient population, we
described a contralateral hypo-perfusion in the
parahippocampal gyrus.27 Why effects were predo-
minantly contralateral remains unclear and we
assumed a possible role of the heterogeneous
patient group included in our study. In the current
study we demonstrated a bilateral involvement of
the parahippocampal region. Decreased rCBF in the
hippocampal region has been described pre-
viously.11,16,18 Medial temporal lobe structures dis-
playing VNS-induced rCBF changes are known to be
involved early in the propagation of abnormal neu-
ronal activity through the epileptic network under-
lying complex partial seizures. A decreased rCBF
may reflect a lowered state of activity in these
cortical areas preventing the propagation of epilep-
tic activity. The same reasoning holds true for the
thalamus as increasing evidence is found that the
thalamus is part of the epileptic network not only in
generalized seizures but also in partial seizures.28,29
The fact that rCBF changes are induced in crucial
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and low-output stimulation train may explain the
acute abortive effect of VNS. This effect was shown
both in animal models for epilepsy and in a clinical
setting.30,31 A substantial number of patients trea-
ted with VNS successfully use the magnet feature of
the device. This magnet allows to manually admin-
ister an additional stimulation train in case of an
aura or an arising seizure in order to interrupt early
epileptic activity.
The chronic baseline condition demonstrated a
decreased tracer uptake in the left thalamus con-
firming our own earlier hypothesis that VNS induces
a chronic inhibitory state in a key structure for
seizure spread resulting in higher thresholds for
propagating epileptic activity.
The finding of an increased rCBF in the thalamus
in the chronic activation conditionmight be a reflec-
tion of the fact that chronic VNS provokes sustained
changes in the thalamus that lead to different reac-
tions when an acute stimulus is administered. This
situationmay be due to local adaptation effects that
alter synaptic neurotransmission.
When correlations with clinical efficacy were
investigated, the pre-VNS baseline scans did not
identify any predictive value of SPECT for future
clinical outcome in patients who are considered for
VNS treatment. Patients who are currently treated
with VNS result from an exclusion process during the
presurgical evaluation process. This yields a patient
population group with many unlocalized or multi-
focal types of epilepsy which may partly account for
this finding.
In the acute stimulation condition, the correla-
tion with positive clinical outcome involves rCBF
changes in limbic structures which is in line with
our reasoning about VNS interfering with the epi-
leptic network as described by Bertram and collea-
gues.28,29 They observed a monosynaptic excitatory
input from the thalamus to the limbic structures of
the medial temporal lobe. Together with known
connections to cortical and subcortical structures,
the thalamus may exhibit a powerful modulating
role in the synchronization of this neuronal circuit.
Vagus nerve stimulation may influence this neuronal
circuitry via inhibition of the thalamus.
The finding of specific changes in rCBF following
an initial single stimulation train may be useful to
identify responders before patients are implanted
with a permanent device. This would imply the
application of SPECT in patients in whom the vagus
nerve is transcutaneously stimulated, e.g. with the
use of transcutaneous electrical nerve stimulation
(TENS) devices.
In conclusion we can state that the findings from
our study investigating VNS-induced rCBF at differ-ent relevant time periods during VNS treatment put
together with other functional imaging studies using
different designs point to a central role of the
thalamus and medial temporal lobe structures in
the mechanism of action of VNS. Further studies
specifically investigating the influence of different
stimulation parameters on rCBF in these structures
in humans and animals may eventually provide prac-
tical guidelines and lead to improved clinical out-
come. Deep brain stimulation is an emerging
treatment for epilepsy and the structures identified
in VNS research have already proven to be valuable
targets for direct stimulation.32,33 Performing func-
tional imaging study designs in patients treated with
VNS and DBSmay be an interesting avenue to further
clarify the mechanism of action of anti-epileptic
treatments as well as the pathophysiology of epi-
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